Diligence memo · auto-generated · as of July 2, 2026
ResQ Pharma, Inc.
ResQ Pharma, Inc. looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
ResQ Pharma, Inc. operates in Pharmaceuticals, based in CHICAGO.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
ResQ Pharma, Inc. has raised $2.3M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.0M on 2020-06-22.
Most recent recorded round closed around 2022-05-13.
Valuation (modeled)modeled
Provath models ResQ Pharma, Inc. at approximately $3.0M (range $155K–$14M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.31× the median modeled value of Seed Pharmaceuticals companies in 2022–2024 (50 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 27 months.
Last raise 4.1 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 5.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 30% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 5% of those peers.
Closest niche peers: Celeris Therapeutics, Inc., Oligomerix, Inc., 2A Biosciences, Inc., Myosin Therapeutics Inc., Eluciderm Inc..
Peoplefiled
12 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.